Search Results

Neurimmune announced today that it regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid.

Neurimmune announced that primary results of its Phase 1 proof-of-concept study of NI006, a recombinant human antibody to deplete amyloid deposits in ATTR cardiomyopathy, have been presented in Prague at Heart Failure 2023, a scientific congress of the European Society of Cardiology, and published in The New England Journal of Medicine.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Neurimmune AG announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd.

On Friday morning, AstraZeneca’s rare disease group Alexion and Switzerland-based Neurimmune entered into a collaboration and licensing agreement for NI006.

AstraZeneca and Neurimmune have signed an exclusive global collaboration and licensing deal to develop, manufacture and commercialize NI006 for ATTR-CM.

Neurimmune AG announced that it has entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, to develop NI006, an investigational human monoclonal antibody specifically targeting misfolded transthyretin.

The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.